Strathclyde University (United Kingdom)



strathclyde institute of pharmacy and biomedical sciences 

The University of Strathclyde is a research and teaching institution with a strong emphasis on “useful learning” and knowledge exchange. The University offers a wide range of undergraduate and postgraduate instructional programs, as well as research activities. The total research funding for the biological and pharmaceutical sciences since 2001 is £21.9M. It is creating a unique Technology & Innovation Centre to work with industry – an investment of €100 million. Strathclyde Institute of Pharmacy and Biomedical Sciences (SIPBS) is a top UK School of Pharmacy and a leading centre for research and training focussed on the discovery, development and delivery of better medicines. SIPBS also houses the Scottish Metabolomic Facility (ScotMet).

The Coordinating Team

Brian McNeil  (Project Co-ordinator)

heads the Strathclyde Fermentation Centre (SFC) has been a leading centre for research into fermentation and cell culture processes, and industrial bioprocessing for over 20 years. SFC has received major funding from industry partners including major biotechnology companies such as Roche, DSM, GSK, Eli Lilly, and instrumentation companies including FossNIRsystems, Thermo and Applikon b.v. The SFC's expertise is on fermentation physiology, real time bioprocess monitoring using Near and Mid Infrared spectroscopy, microbial stress in fermenter systems, fermenter design and scale translation. 

Linda Harvey

Mariana Fazenda

Christina Viegelmann


RuAngelie Edrada-Ebel

heads the Natural Products Metabolomics Group (NPMG) at SIPBS and has developed algorithms to efficiently detect the production of interesting microbial secondary metabolites during the cultivation and production processes that would assist in maintaining or enhancing synthesis of the desired compounds. Our isolation techniques and procedures involving high-throughput flash and medium pressure chromatography is the strength of our marine natural products laboratory. The mass spectrometry laboratories at SIPBS are of the most recent state of the art facilities to solve a variety of problems in chemical profiling and metabolomics. Three high resolution Orbitraps and six low resolution MS instruments as well as additional facility at the Department of Pure and Applied Chemistry where SIPBS share the use of the MALDI-TOF for high MW compounds or cell localization studies. The NMR facilities at the University of Strathclyde are well-equipped with two 400MHz, two 500MHz, and a 600MHz. The metabolomics facility at SIPBS as also the necessary software (SIEVE, MZmine, ALICE, and SIMCA P+) while NPMG has the updated Marine Natural Products databases (MarinLit and Antibase) to process and analyze huge data files generated from both MS and NMR. NPMG is also equipped with most recent gradient flash/medium pressure chromatography to accomplish high-throughput separation and isolation on biologically active extracts and fractions.

Tong Zhang

Lynsey MacIntyre

Ahmed Tawfike


Alan Harvey

heads the Strathclyde Innovations in Drug Research (SIDR) is based within the Strathclyde Institute of Pharmacy & Biomedical Sciences (SIPBS). SIDR offers contract screening services and access to an extensive and highly diverse natural products library.The rapid screening laboratory has developed in the last 10 years from an industry-funded drug discovery facility based on natural product screening. It is equipped for drug discovery assays and for preliminary in vitro toxicology assessments. The lab is equipped with automated liquid handling instruments and plate readers for absorbance, fluorescence, time-resolved fluorescence, luminescence and radiometric measurements. Molecular and cell-based assays are run routinely, and the lab is equipped for culturing mammalian cells and ACDP Group 2 bacteria and parasites. The current range of assays covers tragets relevant to cancer, infections, diabetes, cardiovascular disease and neurological disorders. Samples can also be assessed on in vitro toxicity assays. These include measurement of cytotoxicity in mammalian cells (human, mouse, rat, hamster), determination of effects on the cell cycle using flow cytometry, effects on hERG channels as a predictor of cardiotoxicity, micronucleus formation in mammalian cells to test for genotoxic effects, and induction of Hprt mutations to test for mutagenic effects in mammalian cells.

Louise Young

Carol Clements

Grainne Abbott 


SeaBioTech is funded by the European Commission within its FP7 Programme, under the thematic area KBBE.2012.3.2-01 with Grant Number 311932